U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks

Johnson & Johnson

Market Cap: US$630.9b

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Bristol-Myers Squibb

Market Cap: US$132.4b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Zoetis

Market Cap: US$30.9b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Pfizer

Market Cap: US$154.2b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Amgen

Market Cap: US$225.6b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

AbbVie

Market Cap: US$438.2b

A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Merck

Market Cap: US$323.0b

Operates as a healthcare company worldwide.

Phibro Animal Health

Market Cap: US$1.4b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Gilead Sciences

Market Cap: US$165.0b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Perrigo

Market Cap: US$1.8b

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.

Qiagen

Market Cap: US$9.1b

Provides sample to insight solutions that transform biological samples into molecular insights worldwide.

Danaher

Market Cap: US$147.2b

Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Royalty Pharma

Market Cap: US$33.3b

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

Viatris

Market Cap: US$18.7b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

AnaptysBio

Market Cap: US$1.6b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Hisamitsu Pharmaceutical

Market Cap: US$8.2b

Manufactures and sells pharmaceuticals in Japan.

Latigo Biotherapeutics

Market Cap: US$1.2b

Develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.

Odyssey Therapeutics

Market Cap: US$1.1b

A clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.

Halozyme Therapeutics

Market Cap: US$11.6b

A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

Vaxcyte

Market Cap: US$8.7b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

BioNTech

Market Cap: US$23.3b

Engages in the development and commercialization of immunotherapies in Germany.

UroGen Pharma

Market Cap: US$2.3b

A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Septerna

Market Cap: US$1.8b

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Avantor

Market Cap: US$9.3b

Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

BioLife Solutions

Market Cap: US$1.7b

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

Stevanato Group

Market Cap: US$5.6b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

Braveheart Bio

Market Cap: US$1.8b

A clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

Amylyx Pharmaceuticals

Market Cap: US$2.5b

A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

Sarepta Therapeutics

Market Cap: US$1.8b

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

ACADIA Pharmaceuticals

Market Cap: US$5.1b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Biogen

Market Cap: US$30.6b

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

MeiraGTx Holdings

Market Cap: US$1.2b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

Trulieve Cannabis

Market Cap: US$1.7b

Operates as a cannabis retailer in the United States.

Arcus Biosciences

Market Cap: US$3.7b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Organon

Market Cap: US$3.6b

Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

Olema Pharmaceuticals

Market Cap: US$1.0b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.